caticonslite_bm_alt

Biotech Analyst Bullish on BIIB


Mark Schoenebaum, ISI Group analyst, explains how BIIB can triple its dividend in three years. “This growth exists nowhere else in large cap pharma or biotech,” he says.

Melissa Lee anchors a fast-paced discussion among four professional Wall Street traders. An hour after the bell Fast Money hosts one of the best trading discussions of the day.

Video © and provided by CNBC.

<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.